Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 15;13:831660. doi: 10.3389/fimmu.2022.831660

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Tang, Zhang, Lu, Tian, Liu, Luo, Qiu, Xu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Melatonin prevents retinal pericyte loss in diabetes retinopathy. (A) Representative images of IB4 (green) and NG2 (gray) immunolabeling in normal control and diabetic rat retinas with or without melatonin treatment. (B) Quantification of pericyte coverage. (C) NG2 expression in normal control and diabetic rat retinas with or without melatonin treatment (n = 4 retinas per group). (D) Representative images of IB4 (green), IBA-1 (red), and NG2 (blue) immunolabeling in normal control and 8-week diabetic rat retinas with or without melatonin treatment. Endothelial loss is indicated by white arrowheads. Data are expressed as mean ± SEM (n = 3 retinas per group). N, normal control group; M, melatonin treatment group; D, diabetes group; D+M, diabetes with melatonin treatment group; **p < 0.01, ***p < 0.001 by one-way ANOVA. Scale bar, 50 μm.